Prime Medicine
Prime Medicine's revenue rose 55.3% to $5 million in fiscal 2025. Its operating margin was −4,498.1%, up from −6,787.4% a year earlier. Free cash flow was −$167 million. The diluted share count rose 25.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Prime Medicine does
Prime Medicine is a biotechnology company with no products on the market. It develops gene editing medicines based on Prime Editing, a technology it says can rewrite, replace or repair DNA without making double-stranded breaks in it. It aims for lasting, possibly curative treatments for diseases caused by known genetic changes.
Its lead program, PM577, targets Wilson disease, a liver disease. It is also working on PM647 for alpha-1 antitrypsin deficiency, another liver disease, and on cystic fibrosis, with support from the Cystic Fibrosis Foundation. A program with Bristol-Myers Squibb edits patients' cells outside the body. Its first such program, PM359 for chronic granulomatous disease, has shown early signs that the edited cells work in treated patients.
Prime Medicine has never earned revenue from product sales. It plans to advance its programs through clinical trials, build its own manufacturing and quality systems, and add collaborations with partners.
Its biggest risks, as it describes them
- It has lost money since it started, expects to keep losing money, and has never had product sales.
- Its cash will not fund its planned operations for long, so it must raise more money, which could dilute shareholders.
- Gene editing is new and Prime Editing is unproven, so its medicines may fail trials or be harder to approve.
- Other gene editing or gene therapy approaches may prove more attractive than Prime Editing.
- Its ability to deliver editors to the right tissues, and its dependence on partners such as Bristol-Myers Squibb.
Income statement
Prime Medicine lost money in fiscal 2025: a net loss of $201 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 254 | 294 | 122 | 190 | 178 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 4.7x | 11.1x | 2.5x | 5.6x | 4.8x |
| Quick ratio | 4.7x | 11.1x | 2.5x | 5.6x | 4.8x |
Cash flow
Projections
Project Prime Medicine's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Prime Medicine reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | −3,552.1% |
| Altman Z'' | −10.13 | −7.15 | −9.21 |
| Accruals ratio | −11.8% | −29.7% | −12.1% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | — | — | — |
Compare
Put Prime Medicine side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Prime Medicine | FY25 | 55.3% | −4,498.1% | −3,607.4% | — | — | — | |
| CG Oncology | FY25 | 254.7% | −4,722.1% | −3,279.2% | — | — | 2 | Compare |
| CRISPR Therapeutics | FY25 | −90.6% | −18,933.7% | −9,855.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
| Roivant Sciences | FY25 | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 5 | 0 | 0 | 0 | 3 | 5 |
| Revenue growth | — | −100.0% | — | — | — | 55.3% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 3 | 70 | 87 | 148 | 155 | 161 |
| Operating income | −1 | −84 | −116 | −205 | −202 | −208 |
| Net income | −3 | −165 | −122 | −198 | −196 | −201 |
| Diluted EPS (US$) | −1.91 | −14.19 | −4.19 | −2.18 | −1.65 | −1.35 |
| Diluted shares (millions) | 3 | 13 | 34 | 91 | 119 | 149 |
| Cash flow | ||||||
| Cash from operations | −6 | −34 | −132 | −165 | −123 | −163 |
| Capital expenditure | 1 | 4 | 16 | 9 | 7 | 4 |
| Free cash flow | −6 | −38 | −148 | −174 | −130 | −167 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 2 | 6 | 14 | 26 | 29 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 37 | 254 | 294 | 122 | 190 | 178 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | — | 302 | 360 | 194 | 298 | 343 |
| Total liabilities | — | 62 | 44 | 61 | 144 | 222 |
| Shareholders' equity | 2 | −156 | 316 | 133 | 153 | 121 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −17.9% | — | — | — | −6,787.4% | −4,498.1% |
| Net margin | −65.5% | — | — | — | −6,566.6% | −4,342.4% |
| Free cash flow margin | −118.7% | — | — | — | −4,363.4% | −3,607.4% |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | −3,552.1% |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | — | −152.2% | −88.2% | −136.9% | −146.8% |
| Return on assets | — | — | −36.8% | −71.5% | −79.7% | −62.8% |
| Net debt to EBITDA | — | — | — | — | — | — |